Overview

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Status:
Recruiting
Trial end date:
2023-11-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals